Haberler

New University Center to Support Competition in Pharmaceutical Prices

New University Center to Support Competition in Pharmaceutical Prices

- PharmAFSU, established at AFSU, will strengthen Türkiye’s pharmaceutical research capacity and help promote greater balance in drug prices through generic drug studies

- CoHE President Özvar: “Türkiye ranks among Europe’s best in higher education infrastructure, scientific research and technology development”

August 12, 2026

 

The Pharmaceutical Research, Bioavailability and Bioequivalence and Phase 1 Clinical Trials Application and Research Center (PharmAFSU), established at Afyonkarahisar Health Sciences University (AFSU), is preparing to contribute to Türkiye’s pharmaceutical research capacity. In addition to Phase 1 clinical trials, the center will conduct studies on generic drugs, with the aim of supporting a competitive environment in pharmaceutical pricing.

The center has been structured in accordance with regulations set by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the Turkish Medicines and Medical Devices Agency (TITCK). It aims to conduct Phase 1 clinical trials in compliance with scientific, ethical and international standards.

The center includes a 12-bed Phase 1 Clinical Research Unit and a two-bed intensive care room. Doctors and nurses will provide 24-hour supervision in the clinical area, which is also equipped with advanced life-support and emergency intervention infrastructure. The center will conduct single- and multiple-dose studies, as well as bioavailability, pharmacokinetic and safety studies.

Volunteer safety, data integrity and international Good Clinical Practice (GCP) standards will serve as the basis for research processes. Temperature-controlled storage systems will be used for investigational products and biological samples, while all data will be recorded securely and in a fully traceable manner.

 

“It Will Make a Significant Contribution to Our Country’s Research Capacity”

CoHE President Erol Özvar stated that Türkiye ranks among Europe’s best in terms of higher education infrastructure, scientific research and technology development, adding, “We attach great importance to strengthening the research infrastructure of our universities. I believe that PharmAFSU, established at AFSU, will also make a significant contribution to our country’s research capacity.”

PharmAFSU Director Prof. Müjgan Ercan Karadağ said the center was the only one in Türkiye to bring three units together under a single roof. “The fact that we have a bioanalytical laboratory, which is the most fundamental component of a Clinical Research Center, sets us apart from existing systems in Türkiye,” she said.

Karadağ said the center’s infrastructure had been completed, adding, “We have prepared and completed all the quality requirements. Once our application is submitted to TITCK and we receive our activity authorization, we will contact sponsor companies and launch studies.”

 

- “It Will Be Türkiye’s 22nd Phase 1 Center”

Explaining that a drug goes through four phases before it can receive marketing authorization, Karadağ said, “There are already 21 Phase 1 Clinical Research Centers in Türkiye. Once we receive our activity authorization, we will become Türkiye’s 22nd Phase 1 Clinical Research Center.”

PharmAFSU Deputy Director Assoc. Prof. Jale Akgöl said clinical trials establish the safety profile of new drugs in humans. Akgöl said, “In Phase 1, a drug is administered to humans for the first time and its safety profiles are established. Our center has been structured specifically for Phase 1 studies.”

Highlighting the importance of clinical trials, particularly in oncology and hematology, Akgöl said, “Volunteers can gain access to innovative medicines without having to wait through all the stages of development, which can take years. This is particularly valuable in oncology and hematology.”

PharmAFSU Deputy Director Dr. Hasan Memiş said the center would conduct studies on generic drugs in particular, adding, “We have plans to encourage the production of generic drugs and create a competitive environment in pharmaceutical pricing.”

PharmAFSU Laboratory Supervisor Mesut Aslan said the laboratory infrastructure had been established in accordance with international standards. “Our laboratories have been structured to meet all the requirements of the FDA, EMA and TITCK,” he said.

The center at AFSU aims to make an academic and scientific contribution to Türkiye’s pharmaceutical development and clinical research capacity.

Update Date: 12.08.2026
Images